Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
|Videos|February 7, 2014
A Phase I/Ib Study of the CDK Inhibitor Dinaciclib in CLL
Author(s)John C. Byrd, MD
John C. Byrd, MD, from OSUCCC – James, describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Advertisement
Clinical Pearls
John C. Byrd, MD, director of the division of hematology and a CLL specialist at the Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
- Dinaciclib is a second-generation selective inhibitor of CDKs 1, 2, 5, and 9
- This agent was evaluated in a phase I/Ib expansion study in patients with relapsed or refractory CLL
- Unlike early CDK inhibitors, dinaciclib induced a high response rate (65-70%) and durable remissions
Advertisement
Related to this article
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5